Allosteric Modulation of Adenosine A2A Receptors as a New Therapeutic Avenue

• Published in: International journal of molecular sciences Vol. 23; no. 4; p. 2101
• Main Authors: Korkutata, Mustafa, Agrawal, Lokesh, Lazarus, Michael
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 14.02.2022; MDPI
• Subjects: Adenosine; Blood vessels; Cardiac stress tests; Clinical trials; Cloning; Dopamine; Enzymes; FDA approval; Inflammation; Ischemia; Kinases; Ligands; Microscopy; Proteins; Review; Sickle cell disease; Sleep; Thymus gland; United States > US
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23042101

The therapeutic potential of targeting adenosine A2A receptors (A2ARs) is immense due to their broad expression in the body and central nervous system. The role of A2ARs in cardiovascular function, inflammation, sleep/wake behaviors, cognition, and other primary nervous system functions has been extensively studied. Numerous A2AR agonist and antagonist molecules are reported, many of which are currently in clinical trials or have already been approved for treatment. Allosteric modulators can selectively elicit a physiologic response only where and when the orthosteric ligand is released, which reduces the risk of an adverse effect resulting from A2AR activation. Thus, these allosteric modulators have a potential therapeutic advantage over classical agonist and antagonist molecules. This review focuses on the recent developments regarding allosteric A2AR modulation, which is a promising area for future pharmaceutical research because the list of existing allosteric A2AR modulators and their physiologic effects is still short.